Bringing together scientists, physicians, patient families & funders in a collaborative effort to explore and advance innovations in the battle against Alzheimer's!
All Monday June 3rd sessions will be held at the University of the Sciences / McNeil Science and Technology Center, located at 4308 Woodland Ave, Philadelphia, PA 19026.
Sunday, June 2, 2019 |
|
---|---|
7:00pm - 9:00pm | VIP Reception at New Deck Tavern - 3408 Sansom St, Philadelphia, PA 19104 |
Monday, June 3, 2019 |
|
7:45am - 8:50am | Registration & Breakfast |
9:00am - 9:05am | Opening remarks by Max Tokarsky, Founder & CEO of InvestAcure |
9:05am - 9:15am | Optimism and Lessons: Advances in Alzheimer’s Diagnostics and Treatment Howard Fillit, MD, Founding Executive Director and Chief Science Officer, ADDF |
9:15am - 9:30am | Solving The Alzheimer's Puzzle: A Portfolio Approach to Clinical Trials George Perry, PhD, Professor of Biology & Chemistry, Chief Scientist, Brain Health Consortium, The University of Texas at San Antonio |
Session I: Alzheimer's Research Progress & Early Detection Breakthroughs |
|
9:30am - 9:45am |
The Case for Combination Therapy in Alzheimer's Disease
Hugo Geerts, PhD, Chief Scientist, In Silico Biosciences, Inc.
|
9:45am - 10:00am |
Accurate Alzheimer's Diagnostics in the Palm of Your Hand
Rhoda Au, PhD, Professor of Anatomy & Neurobiology, Boston University Schools of Medicine
|
10:00am - 10:15am | LymPro: The Immune-based Blood Test for Alzheimer’s Paula Trzepacz, MD, Scientific Advisor for Alzheimer’s Diagnostics, Todos Medical |
10:15am - 10:30am |
Panel Discussion and Q & A |
10:30am - 11:00am |
Break |
Session II. From News Headlines to Patients: Clinical Trial Ready Drugs (Part 1) |
|
11:00am - 11:15am | NDX-1017: Restoring Lives by Advancing Bold Therapies, Thoughtfully and Urgently Leen Kawas, PhD, President & CEO, Athira Pharma |
11:15am - 11:30am | The Yin and Yang of the Brain: How to Equilibrate a Malfunctioning Brain Using Epigenetics Tamara Maes, PhD, Chief Scientific Officer, Oryzon Genomics |
11:30am - 11:45am | Bryostatin: A Natural Compound from the Depths of the Ocean to Help Restore Neural Pathways and Reverse Alzheimer's Memory Loss Dan Alkon, MD, President & Chief Scientific Officer, Neurotrope |
11:45am - 12:00pm | BPN14770: A Novel Approach to Preserve Neuronal Connections and Prevent Memory Loss in Alzheimer's Patients Mark E. Gurney, PhD, MBA, Chairman & CEO, Tetra Discovery Partners Inc. |
12:00pm - 12:15pm | AGB-101: A Novel Approach to Stop Alzheimer's at its Earliest Signs Sharon Rosenzweig-Lipson, PhD, Vice President of Research and Development, AgeneBio. |
12:15pm - 12:30pm |
Panel Q & A |
12:30pm - 1:30pm |
Lunch |
Session III. From News Headlines to Patients: Clinical Trial Ready Drugs (Part 2) |
|
1:30pm - 1:45pm | Alz-801 Phase 3 -Ready Program: A Targeted Therapy for Alzheimer's Disease Martin Tolar, MD, PhD, Founder, President & CEO, Alzheon, Inc. |
1:45pm - 2:00pm | Troriluzole: Novel Drug that Targets Glutamate as a Potential Treatment for Alzheimer's Disease Irfan Qureshi, MD, Executive Director of Neurology, Biohaven Pharmaceuticals |
2:00pm - 2:15pm | Memtin - Patented Hormone Replacement Therapy for Slowing Cognitive Decline in Alzheimer’s Disease and Other Dementias Nik Tezapsidis, PhD, President & CEO, Neurotez, Inc. |
2:15pm - 2:30pm | Hitting 3 Birds with One Pill: How SM07883 May Prevent Tau, Amyloid and Inflammation in Alzheimer’s Disease David Herman, PhD, Director, Medical Affairs and Benoît Melchior, PhD, Director, Biology, Samumed LLC |
2:30pm - 2:45pm |
Panel Discussion and Q & A |
2:45pm - 3:15pm |
Break |
Session IV. Solving the Investment Valley of Death and Turning Science Into Cure
|
|
3:15pm - 3:30pm | Alzheimer's: What if Drug Companies Were Owned by Millions Waiting for a Cure? - The Spare Change Investment Solution Max Tokarsky, Founder & CEO of InvestAcure, PBC |
3:30pm - 3:45pm | A Solution to the ‘Valley of Death’ in Alzheimer’s Finance David Weild, Chairman & CEO, Weild & Co, Co-founder & Vice Chairman, InvestAcure, PBC |
3:45pm - 4:00pm | Securing Alzheimer's Investment: From Spare Change to $1 Billion Ken Abramowitz, Co-Founder & Managing General Partner, NGN Capital, Chief Investment Officer, InvestAcure, PBC |
4:00pm - 4:15pm |
Panel Discussion and Q & A |
4:15pm - 4:45pm |
Break |
Session V. Lifestyle Interventions: Nutrition, Meditation & Physical Exercise |
|
4:45pm - 5:00pm | Science of Prevention: The 5 Alzheimer’s Busting Habits Adeboye Adejare, PhD, Professor of Pharmaceutical Sciences, University of the Sciences |
5:00pm - 5:15pm | African Dance: Can It Be a Culturally Salient Way to Lower the Risk of Alzheimer’s Disease and Related Dementias for African Americans? Kathryn Jedrziewski, PhD, Deputy Director of the Institute on Aging (IOA), University of Pennsylvania |
5:15pm - 5:30pm | MapHabit: The Secret Sauce for Memory Health Matt Golden, Co-Founder & CEO, MapHabit |
5:30pm - 5:45pm |
Panel Discussion and Q & A |
5:45pm - 8:00pm |
Together We Cure! Closing Reception |